Citations

Showing 10 of 108119 citations.

Osteomeniscal Impact Edema (OMIE): Description of a Distinct MRI Finding in Displaced Flap Tears of the Medial Meniscus, with Comparison to Posterior Root Tears
Krych, Aaron J. , Wu, Isabella T. , Desai, Vishal , Kennedy, Nicholas I. , Littrell, Laurel A. , Collins, Mark S., Saris, Daniël B.F. , Stuart, Michael D. , Desai, Vishal S. , Krych, Aaron J

Mayo Clinic

The Journal of Knee Surgery | March 28, 2019 | Volume: 33 | Issue: 07 | Pages: 659-665

10.1055/s-0039-1683938 | PMID 30921819 Get It

AbstractBone marrow edema (BME) can be a late finding in osteoarthritis or a sign of subchondral insufficiency. The purpose of this study was to describe the magnetic resonance imaging (MRI) finding we refer to as “osteomeniscal impact edema” (OMIE), or reactive BME adjacent to a displaced meniscus flap tear. In addition, this edema pattern is compared with a control group of medial meniscus posterior root tears (MMPRT) with subchondral insufficiency edema. MRI records from 2000 to 2017 were retrospectively reviewed for studies that showed the presence of a medial meniscus displaced flap tear and an adjacent area of BME. The selected MRIs were matched to an equal number of MMPRT MRI studies. All MRI studies were assessed for cartilage surface grade using the modified Outerbridge classification system and for the extent of accompanying structural abnormalities using the whole-organ magnetic resonance imaging score. Descriptive statistics and hypothesis testing were utilized to compare the MRI findings between groups. Twenty-two flap tear (OMIE group) patients with a mean age of 57 (SD: 15) and 22 root tear (MMPRT) group patients with a mean age of 61 (SD: 10) were included. MRIs in the OMIE group showed a distinctive pattern of focal, peripheral edema adjacent to the meniscus flap tear, compared with more diffuse, central edema in the MMPRT group. Quantitatively, MRIs of the MMPRT group showed significantly worse mean femoral Outerbridge scores (3.72 vs. 2.68, p < 0.0001), more severe central (1.63 vs. 0.5, p = 0.0007) and posterior (0.31 vs. 0.0, p = 0.04) subchondral edema grades, and a higher incidence of tibial subchondral fractures (3 vs. 0, p = 0.036). Meniscus flap tears may present with a distinct MRI pattern of focal, adjacent, peripheral edema, which we refer to as OMIE. Patients with meniscus flap tears showed significantly less arthritic change, lower subchondral edema grades, and a lower incidence of insufficiency fractures and subchondral collapse compared with the diffuse overload edema pattern found with root tears. The Level of Evidence for this study is III.
Medicare Reimbursement for General Surgery Procedures
Haglin, Jack M. , Eltorai, Adam E. M. , Richter, Kent R. , Jogerst, Kristen, Jogerst, Kristen M. , Daniels, Alan H.

Mayo Clinic

Annals of Surgery | March 28, 2019 | Volume: 271 | Issue: 1 | Pages: 17-22

10.1097/sla.0000000000003289 | PMID 30921048 Get It

Objective: The purpose of this study is to evaluate monetary trends from 2000 to 2018 in Medicare reimbursement rates for the most common general surgery procedures. Summary Background Data: A complete understanding of financial trends in general surgery in the United States is lacking. As such, an evaluation of trends in reimbursement rates in general surgery is important for defining the specialty's current and future financial health. Methods: The Physician Fee Schedule Look-Up Tool from the Centers for Medicare and Medicaid Services was queried for each of the 20 top codes top in general surgery. The total raw percent change in Medicare reimbursement rate for each procedure from 2000 to 2018 was calculated and averaged. All data was corrected for inflation. Both average annual and total percentage change were calculated based on these adjusted trends. Compound annual growth rate was calculated using the adjusted data. Results: After adjusting all data for inflation, the reimbursement rate for all included procedures decreased by an average of 24.4% throughout the study period. During this time, the adjusted reimbursement rate decreased by an average of 1.4% each year with an average compound annual growth rate of −1.6%. Conclusion: After adjusting for inflation, Medicare reimbursement rates in general surgery have steadily decreased from 2000 to 2018. It is important that these trends are understood and considered by surgeons, healthcare administrators, and policy-makers in order to develop and implement agreeable models of reimbursement while ensuring access to quality general surgery care in the United States.
Patients’ Medical and Psychosocial Experiences After Detection of a CDH1 Variant With Multigene Panel Testing
Hamilton, Jada G. , Brandt, Amanda , Brower, Jamie , Symecko, Heather , Christian, Stephanie N. , Harstad, Tricia, Offit, Kenneth , Long, Jessica M. , Salo‐Mullen, Erin E. , Couch, Fergus J. , Garber, Judy E. , Robson, Mark E. , Domchek, Susan M.

Mayo Clinic

JCO Precision Oncology | March 28, 2019 | Volume: No volume available | Issue: 3 | Pages: 1-14

10.1200/po.18.00300 | PMID 31511843 Get It

PURPOSE Germline CDH1 pathogenic variants (PV) are associated with hereditary diffuse gastric cancer and lobular breast cancer. Although prevalence of CDH1 PV is low in the general population, detection of these variants is increasing with the growing use of multigene panel testing. Little is known about the experiences of individuals tested for CDH1 variants in the multigene panel testing era. METHODS Participants recruited from the Prospective Registry of Multiplex Testing completed a cross-sectional self-report survey regarding CDH1 genetic testing experiences, medical management, and psychosocial adaptation. RESULTS Discordance existed in interpretations of CDH1 results; 13.3% of cases had disagreements in variant classifications among commercial laboratories, and 21.4% had disagreements between participant self-report and ClinVar classification. Survey data were available from 57 individuals reporting either PV (n = 16) or variants of uncertain significance (VUS; n = 41). Those with PV were more likely than those with VUS to report receiving a recommendation for prophylactic gastrectomy, although only 40.0% of those with PV received this recommendation. Participants with VUS were less satisfied with their health care providers’ knowledge and reported less CDH1 knowledge, distress, and worry about discrimination. Participants with PV perceived greater breast cancer risks, but similar gastric cancer risks, as those with VUS. CONCLUSION Few individuals with CDH1 PV report receiving recommendations for prophylactic gastrectomy, and no differences in perceived gastric cancer risk were observed based on participants’ CDH1 results, suggesting serious unmet informational needs.
Hearing Preservation and Auditory Rehabilitation in Skull Base Surgery
Carlson, Matthew L. , Jethanamest, Daniel

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | March 28, 2019 | Volume: 80 | Issue: 02 | Pages: 109-110

10.1055/s-0039-1683881 | PMID 30931216 Get It

A Potentially Volatile Situation
Langman, Loralie J., Jannetto, Paul J. , Reichard, Ross R.

Mayo Clinic

Clinical Chemistry | March 28, 2019 | Volume: 65 | Issue: 4 | Pages: 598-599

10.1373/clinchem.2018.297978 | PMID 30923064 Get It

Letter: vitamin D deficiency and autoimmune hepatitis – from research to treatment—authors' reply
Ebadi, Maryam , Czaja, Albert J. , Montaño‐Loza, Aldo J. , Montano-Loza, Aldo J

Mayo Clinic

Alimentary Pharmacology & Therapeutics | March 28, 2019 | Volume: 49 | Issue: 8 | Pages: 1104-1105

10.1111/apt.15154 | PMID 30920035 Get It

Linked ContentThis article is linked to Ebadi et al and Wang et al papers. To view these articles, visit https://doi.org/10.1111/apt.15029 and https://doi.org/10.1111/apt.15147.
Randomized clinical trial of liposomal bupivacaine transverse abdominis plane block versus intrathecal analgesia in colorectal surgery
Osagiede, Osayande , Merchea, Amit , Ball, Colleen T. , Bojaxhi, Elird , Jacob, Adam K. , Naessens, James M. , Osagiede, Osayande , Colibaseanu, Dorin , Panchamia, Jason K. , Kelley, Scott R. , Larson, David W.

Mayo Clinic

British Journal of Surgery | March 28, 2019 | Volume: 106 | Issue: 6 | Pages: 692-699

10.1002/bjs.11141 | PMID 30919948 Get It

Abstract Background Transverse abdominis plane (TAP) block is considered an effective alternative to neuraxial analgesia for abdominal surgery. However, limited evidence supports its use over traditional analgesic modalities in colorectal surgery. This study compared the analgesic efficacy of liposomal bupivacaine TAP block with intrathecal (IT) opioid administration in a multicentre RCT. Methods Patients undergoing elective small bowel or colorectal resection were randomized to receive TAP block or a single injection of IT analgesia with hydromorphone. Patients were assessed at 4, 8, 16, 24 and 48 h after surgery. Primary outcomes were mean pain scores and morphine milligram equivalents (MMEs) administered within 48 h after surgery. Secondary outcomes included duration of hospital stay, incidence of postoperative ileus and use of intravenous patient-controlled analgesia. Results In total, 209 patients were recruited and 200 completed the trial (TAP 102, IT 98). The TAP group had a 1·6-point greater mean pain score than the IT group at 4 h after surgery, and this difference lasted for 16 h after operation. The TAP group received more MMEs within the first 24 h after surgery than the IT group (median difference in MMEs 10·0, 95 per cent c.i. 3·0 to 20·5). There were no differences in MME use at 24 and 48 h, or with respect to secondary outcomes. Conclusion IT opioid administration provided better immediate postoperative pain control than TAP block. Both modalities resulted in low pain scores in patients undergoing elective colorectal surgery and should be considered in multimodal postoperative analgesic plans. Registration number: NCT02356198 ( http://www.clinicaltrials.gov).
Outcomes of orthotopic heart transplantation and left ventricular assist device in patients aged 65 years or more with end-stage heart failure
Harmon, David , Tecson, Kristen M. , Jamil, Aayla K. , Felius, Joost , Gonzalez‐Stawinski, Gonzalo V. , Joseph, Susan , Hall, Shelley , Harmon, David M , Hall, Shelley A

Mayo Clinic

Baylor University Medical Center Proceedings | March 28, 2019 | Volume: 32 | Issue: 2 | Pages: 177-180

10.1080/08998280.2019.1576095 | PMID 31191122 Get It

Orphan disease status of cancer cachexia in the USA and in the European Union: a systematic review
Anker, Markus S. , Holcomb, Richard , Muscaritoli, Maurizio , Haehling, Stephan von , Haverkamp, Wilhelm , Jatoi, Aminah , Morley, John E. , Strasser, Florian, Landmesser, Ulf , Landmesser, Ulf , Coats, Andrew J.S. , Anker, Stefan D.

Mayo Clinic

Journal of Cachexia, Sarcopenia and Muscle | March 28, 2019 | Volume: 10 | Issue: 1 | Pages: 22-34

10.1002/jcsm.12402 | PMID 30920776 Get It

Abstract Background Cachexia has significant impact on the patients' quality of life and prognosis. It is frequently observed in patients with cancer, especially in advanced stages, but prevalence data for the overall population are lacking. Good quality estimates of cancer cachexia in general and for each of the major cancer types would be highly relevant for potential treatment development efforts in this field. Both the USA and European Union (EU) have implemented special clinical development rules for such rare disorders what are called ‘orphan diseases’. The cut‐off level for a disease to be considered an orphan disease in the USA is 200 000 people (0.06% of the population) and EU is 5 per 10 000 people (0.05% of the population). Methods For this systematic review, we searched at PubMed (from inception to 31 January 2018) to identify clinical studies that assessed the prevalence of cachexia in cancer patients at risk. Studies reporting the prevalence of either cancer cachexia or wasting disease in the top‐10 cancer types and 4 other selected cancer types known to be particularly commonly complicated by cachexia were included in this analysis (i.e. prostate cancer, breast cancer, colorectal cancer, melanoma, endometrial cancer, thyroid cancer, urinary bladder cancer, non‐hodgkin lymphoma, lung cancer, kidney and renal pelvis cancer, head and neck cancer, gastric cancer, liver cancer, and pancreatic cancer). We calculated the current burden of cancer cachexia, disease by disease, in the USA and in the EU and compared them to the current guidelines for the definition of orphan disease status. Results We estimate that in 2014 in the USA, a total of 527 100 patients (16.5 subjects per 10 000 people of the total population), and in 2013 in the EU, a total of 800 300 patients (15.8 subjects per 10 000 people of the total population) suffered from cancer cachexia (of any kind). In the 14 separately analysed cancer types, the prevalence of cancer cachexia in the USA ranged between 11 300 (0.4/10 000, gastric cancer) and 92 000 patients (2.9/10 000, lung cancer) and in the EU between 14 300 (0.3/10 000, melanoma of the skin) and 150 100 (3.0/10 000, colorectal cancer). Conclusions The absolute number of patients affected by cancer cachexia in each cancer group is lower than the defined thresholds for orphan diseases in the USA and EU. Cancer cachexia in each subgroup separately should be considered an orphan disease.